Piper Sandler Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM) had its price objective dropped by analysts at Piper Sandler from $70.00 to $55.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler’s price objective points to a potential upside of 3.66% from the company’s current price.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. downgraded shares of Tempus AI from an “overweight” rating to a “neutral” rating and raised their target price for the company from $50.00 to $55.00 in a research note on Tuesday, February 25th. Guggenheim reissued a “buy” rating on shares of Tempus AI in a research note on Tuesday, February 25th. Needham & Company LLC raised their target price on shares of Tempus AI from $56.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, February 25th. Wolfe Research downgraded shares of Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.73.

Tempus AI Stock Performance

Shares of NASDAQ TEM opened at $53.06 on Tuesday. Tempus AI has a 1 year low of $22.89 and a 1 year high of $91.45. The firm’s 50 day moving average price is $53.38 and its 200 day moving average price is $52.56. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Insider Activity

In other Tempus AI news, major shareholder Bradley A. Keywell sold 395,800 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the transaction, the chief accounting officer now owns 57,237 shares of the company’s stock, valued at $3,434,220. This trade represents a 19.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,823,701 shares of company stock worth $320,906,059.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TEM. Operose Advisors LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $25,000. First Horizon Advisors Inc. acquired a new stake in Tempus AI during the third quarter valued at approximately $30,000. Farther Finance Advisors LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $34,000. Prestige Wealth Management Group LLC lifted its stake in Tempus AI by 910.4% during the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new stake in Tempus AI during the fourth quarter valued at approximately $49,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.